Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Continuous positive airway pressure for moderate to severe COVID-19 acute respiratory distress syndrome in a resource-limited setting

Anbesan Hoole, Sahar Qamar, Ayesha Khan, Mariam Ejaz
ERJ Open Research 2022 8: 00536-2021; DOI: 10.1183/23120541.00536-2021
Anbesan Hoole
Dept of Internal Medicine, Bach Christian Hospital, Abbottabad, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anbesan Hoole
  • For correspondence: anbesan.hoole@gmail.com
Sahar Qamar
Dept of Internal Medicine, Bach Christian Hospital, Abbottabad, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayesha Khan
Dept of Internal Medicine, Bach Christian Hospital, Abbottabad, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariam Ejaz
Dept of Internal Medicine, Bach Christian Hospital, Abbottabad, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Continuous positive airway pressure is an efficacious and cost-effective modality of treatment for #COVID19 ARDS, particularly in resource-poor settings with late referrals to overwhelmed intensive care units https://bit.ly/3dKwXwP

To the Editor:

Management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated acute respiratory distress syndrome (coronavirus disease 2019 (COVID-19) ARDS or CARDS) has challenged the health systems of developed countries, and even more so the health systems of resource-poor settings [1]. Within this context, continuous positive airway pressure (CPAP) has been trialled as an alternative, less resource-intensive respiratory support to early invasive mechanical ventilation (IMV) [2] with promising results, and now features in some major guidelines [3]. However, there are limited studies from resource-poor settings that have been impacted massively by COVID-19. We retrospectively analysed the completed survival outcomes and characteristics for the exclusive use of CPAP for moderate-to-severe CARDS as defined by the Kigali criteria [4] in a cohort of patients admitted to Bach Christian Hospital (BCH; Abbottabad, Pakistan) between April and August 2021.

BCH is a small 60-bed secondary level hospital in rural Northern Pakistan (Khyber Pakhtunkhwa Province). A COVID-19 unit was opened at BCH in December 2020 to respond to the surge of severely unwell COVID-19 patients in Pakistan's “second wave”. This contained nine high-dependency unit beds with appropriate step-down patients transferred to another ward. Nursing staff with limited previous critical care experience were trained in the management of critically unwell patients, the use of CPAP and arterial blood gas (ABG) sampling. The unit was staffed by a single nurse and nurse aide.

Patients were admitted to the COVID-19 unit at BCH based on respiratory failure (peripheral oxygen saturation (SpO2) <90% or respiratory rate >30 breaths·min−1) in the presence of a clinical history and examination suggestive of COVID-19 pneumonia with appropriate radiological and laboratory findings. SARS-CoV-2 PCR was performed on patients who could afford it, but was limited due to cost and availability [5]. However, all patients tested had positive results, and COVID-19 antigen testing was implemented from August 2021.

Ethical approval was obtained from the hospital committee for this observational study.

Patients were initially resuscitated with 5 L oxygen (O2) via nasal cannula or 15 L O2 via nonrebreather mask, depending on severity, with a target SpO2 of 95% (figure 1a). After 1 h clinical assessment was performed using ABG, and those with persistent tachypnoea or arterial oxygen tension (PaO2)/inspiratory oxygen fraction (FiO2) ratio <150 mmHg (corresponding to requiring more than >5 L O2 via nasal cannula to maintain SpO2 >90%) were commenced on CPAP at 10 cmH2O, as recommended by United Kingdom guidelines [6] and the initial study from Genoa [2].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

a) Respiratory support algorithm for coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (CARDS); b) completed outcomes for patients admitted with acute hypoxaemic respiratory failure (AHRF) April to August 2021; c) improvement in oxygenation with continuous positive airway pressure (CPAP) for moderate and severe CARDS (results for initial cohort April to May 2021 with complete data; n=31). Data are presented as mean±95% CI. SpO2: peripheral oxygen saturation; RA: room air; O2: oxygen; ABG: arterial blood gases; PaO2: arterial oxygen tension; FiO2: inspiratory oxygen fraction.

Philips Respironics CPAP machines originally intended for home use for obstructive sleep apnoea were used with their default Amara full-face masks, with the addition of antibacterial/antiviral heat and moisture exchange filters. Philips advise a separate inflow attachment for O2 entrainment [7], but in the absence of these pieces, O2 was entrained via a T-tube to the machine end of the CPAP tubing. O2 was supplied from a wall flow meter with a capacity of up to 15 L·min−1.

Clinical status was reassessed by ABG after 1 h on CPAP. Those who had improved on CPAP 10 cmH2O were placed on continuous CPAP for 72 h, as recommended by an Italian protocol [8], with breaks for eating and drinking. Those who failed to improve sufficiently on 10 cmH2O CPAP were given a trial of 15 cmH2O CPAP, which has been described in Italian and Scottish guidelines [9, 10]. If patients improved significantly at 15 cmH2O, that pressure was continued. Otherwise, 10 cmH2O was used for all patients, given the risks of barotrauma at pressures >10 cmH2O. All patients on oxygen, including those on CPAP, were encouraged to undergo prone positioning for ⩾1 h three times daily [11]. Those unable to tolerate complete proning were encouraged to undergo semi-prone positioning.

CPAP weaning was attempted after 72 h of continuous CPAP. CPAP was stopped when PaO2/FiO2 off CPAP was >150 mmHg, or SpO2 >90% was maintained on 5 L O2 via nasal cannula. Patients who failed to wean off CPAP at all were given another 72 h of continuous CPAP and weaning was reattempted afterwards.

Steroids (dexamethasone) with appropriate thromboprophylaxis (rivaroxaban, due to lack of availability of low molecular weight heparin) formed the mainstay of medical management. Remdesivir was not used, due to lack of evidence of efficacy in severe disease, and tocilizumab was used in select patients from July, as per the updated World Health Organization guidelines [12].

149 patients were admitted with suspected COVID-19 acute hypoxaemic respiratory failure at BCH from 9 April to 31 August 2021. 99 patients met criteria for moderate-to-severe ARDS and were commenced on CPAP regardless of age or underlying comorbidities. 76 patients survived on CPAP (figure 1b).

The duration of successful CPAP ranged from 5 to 21 days. Complications on CPAP included barotrauma, particularly with higher pressures. Four patients on 15 cmH2O developed these complications (n=2 pneumothorax, n=2 pneumomediastinum), while only one patient on 10cm H2O had this complication (n=1 pneumomediastinum). The patients with pneumothorax had chest tube insertion, but even so, all five of these patients died. However, this rate of barotrauma (five (5%) out of 99 patients) is similar to that reported elsewhere for noninvasive ventilation (NIV) in CARDS, which is lower than rates observed for IMV [13].

Patients with CARDS demonstrated improvement in oxygenation with CPAP (figure 1c). FiO2 on simple oxygen including nasal cannula was approximated using the Shapiro formula [14], and a white paper from Philips was used to estimated FiO2 on CPAP [7].

No healthcare-associated infections were reported among staff.

Our survival rate on CPAP (76.8% total) is slightly lower than the 83% reported in the original study on CPAP in CARDS from Genoa [2]. However, the original study excluded a significant number of patients who were not considered fit for resuscitation, while all patients received CPAP as per protocol in this study, regardless of pre-morbid state. Our survival rate is significantly higher than the 29% reported in patients treated exclusively with CPAP in another Italian series [15]; however, it is likely that these patients had a greater frequency of underlying comorbidities, as they were classed ineligible for intubation. The CARDS survival rate for CPAP at our centre is not too dissimilar to reported rates (∼80%) from intensive care units (ICUs) employing NIV and IMV in resource-rich settings [16], suggesting that CPAP is feasible as a ceiling of care treatment modality in pandemic circumstances. Even more significantly, the survival rate is higher than the dire outcomes in ICUs employing IMV in resource-poor settings inundated by late referrals [1]. CPAP is less resource-intensive in terms of equipment and staffing, and healthcare workers can be easily trained in its operation. Early implementation of CPAP for CARDS in a non-ICU setting as opposed to late referral to an already overwhelmed ICU for IMV is likely to save many lives.

Significant limitations of this study include its observational nature, retrospective single-centre design and small sample size.

CPAP is an efficacious and cost-effective modality of treatment for CARDS, particularly in resource-poor settings, which now bear most of the pandemic burden.

Acknowledgements

Many thanks to our dedicated nursing staff (Bach Christian Hospital, Abbottabad, Pakistan) for their work with COVID-19 patients and help with data collection, particularly Rizwan Hameed and Shahzad Gill. We are thankful to Luke Cutherell, Musheer Shaukat, Zubaid Inayat and Nabila Michael for their support and encouragement with the work of our COVID-19 unit.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Conflict of interest: The authors have nothing to disclose.

  • Received August 25, 2021.
  • Accepted December 4, 2021.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Biccard BM,
    2. Gopalan PD,
    3. Miller M, et al.
    Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. Lancet 2021; 397: 1885–1894. doi:10.1016/S0140-6736(21)00441-4
    OpenUrlPubMed
  2. ↵
    1. Brusasco C,
    2. Corradi F,
    3. Di Domenico A, et al.
    Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure. Eur Respir J 2021; 57: 2002524. doi:10.1183/13993003.02524-2020
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Attaway AH,
    2. Scheraga RG,
    3. Bhimraj A, et al.
    Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ 2021; 372: n436. doi:10.1136/bmj.n436
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Riviello ED,
    2. Buregeya E,
    3. Twagirumugabe T
    . Diagnosing acute respiratory distress syndrome in resource limited settings: the Kigali modification of the Berlin definition. Curr Opin Crit Care 2017; 23: 18–23. doi:10.1097/MCC.0000000000000372
    OpenUrl
  5. ↵
    1. Schultz MJ,
    2. Gebremariam TH,
    3. Park C, et al.
    Pragmatic recommendations for the use of diagnostic testing and prognostic models in hospitalized patients with severe COVID-19 in low- and middle-income countries. Am J Trop Med Hyg 2021; 104: 34–47. doi:10.4269/ajtmh.20-1515
    OpenUrlPubMed
  6. ↵
    1. Walker J,
    2. Dolly S,
    3. Ng L, et al.
    The role of CPAP as a potential bridge to invasive ventilation and as a ceiling-of-care for patients hospitalized with Covid-19 – an observational study. PLoS One 2020; 15: e0244857. doi: 10.1371/journal.pone.0244857
    OpenUrlPubMed
  7. ↵
    1. Hill P,
    2. Yarascavitch J
    1. Shelly B
    , Hill P, Yarascavitch J. Philips Respironics E30 Ventilator Oxygen Entrainment and FiO2 Estimation. 2020. https://images.philips.com/is/content/Philipsconsumer/campaigns/HC20140401_DG/documents/e30-oxygen-entrainment-and-fio2-estimation-white-paper.pdf
  8. ↵
    1. Radovanovic D,
    2. Rizzi M,
    3. Pini S, et al.
    Helmet CPAP to treat acute hypoxemic respiratory failure in patients with COVID-19: a management strategy proposal. J Clin Med 2020; 9: 1191. doi:10.3390/jcm9041191
    OpenUrl
  9. ↵
    1. Jeschke KN,
    2. Bonnesen B,
    3. Hansen EF, et al.
    Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting. Eur Clin Respir J 2020; 7: 1761677. doi:10.1080/20018525.2020.1761677
    OpenUrl
  10. ↵
    Healthcare Improvement Scotland, Scottish Intercollegiate Guidelines Network. COVID-19 Position Statement: CPAP for COVID-19-Related Respiratory Failure. 2020. https://www.sign.ac.uk/media/1757/sg_cpap_guidance_version_2.pdf
  11. ↵
    1. Winck JC,
    2. Scala R
    . Non-invasive respiratory support paths in hospitalized patients with COVID-19: proposal of an algorithm. Pulmonology 2021; 27: 305–312. doi:10.1016/j.pulmoe.2020.12.005
    OpenUrl
  12. ↵
    1. World Health Organization
    . Therapeutics and COVID-19: Living Guideline. 2021. Available from: www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.3
  13. ↵
    1. Rajdev K,
    2. Spanel AJ,
    3. McMillan S, et al.
    Pulmonary barotrauma in COVID-19 patients with ARDS on invasive and non-invasive positive pressure ventilation. J Intensive Care Med 2021; 36: 1013–1017. doi:10.1177/08850666211019719
    OpenUrl
  14. ↵
    1. Hess D,
    2. MacIntyre NR,
    3. Galvin WF, et al.
    1. Boatright JE,
    2. Jensen MQ
    . Therapeutic gases: management and administration. In: Hess D, MacIntyre NR, Galvin WF, et al., eds. Respiratory Care: Principles and Practice. Burlington, Jones & Bartlett Learning, 2021; pp. 285–319.
  15. ↵
    1. Ramirez GA,
    2. Bozzolo EP,
    3. Gobbi A, et al.
    Outcomes of non-invasive ventilation as the ceiling of treatment in patients with COVID-19. Panminerva Med 2021; in press [https://doi.org/10.23736/S0031-0808.21.04280-4]. doi:10.23736/S0031-0808.21.04280-4
  16. ↵
    1. Pfeifer M,
    2. Ewig S,
    3. Voshaar T, et al.
    Position paper for the state-of-the-art application of respiratory support in patients with COVID-19. Respiration 2020; 99: 521–541. doi:10.1159/000509104
    OpenUrl
PreviousNext
Back to top
Vol 8 Issue 1 Table of Contents
ERJ Open Research: 8 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Continuous positive airway pressure for moderate to severe COVID-19 acute respiratory distress syndrome in a resource-limited setting
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Continuous positive airway pressure for moderate to severe COVID-19 acute respiratory distress syndrome in a resource-limited setting
Anbesan Hoole, Sahar Qamar, Ayesha Khan, Mariam Ejaz
ERJ Open Research Jan 2022, 8 (1) 00536-2021; DOI: 10.1183/23120541.00536-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Continuous positive airway pressure for moderate to severe COVID-19 acute respiratory distress syndrome in a resource-limited setting
Anbesan Hoole, Sahar Qamar, Ayesha Khan, Mariam Ejaz
ERJ Open Research Jan 2022, 8 (1) 00536-2021; DOI: 10.1183/23120541.00536-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Acute lung injury and critical care
  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Streptococcus pneumoniae re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021
  • Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
  • The use of digital web-based video training for correct inhalation technique during the COVID-19 pandemic
Show more Research letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society